Questionnaire

1. People living with asthma in South Africa face a 100-fold increased risk of dying from an exacerbation compared with people who have asthma and live in Europe.

2. In the management of severe or life-threatening asthma exacerbation, HFNO has been found to significantly reduce:

3. A UK observational cohort study found that patients with asthma who had a frequent pattern of intermittent OCS prescriptions were more likely to be:

4. A UK observational cohort study found that the association between patterns of intermittent OCS prescription and risk of OCS-related adverse outcomes remained consistent when stratified by:

5. Compared to patients with asthma who are dependent on corticosteroid treatment, those with corticosteroid-independent asthma have a significantly reduced risk for:

6. Importantly, clinical remission of asthma is not the same as a cure, as there is a risk of subclinical inflammation, airway remodelling and relapse.

7. Remission is an emerging concept of sustained absence of asthma disease in the context of biologic treatments. Core criteria over 12 months are:

8. The percentage of patients with a history of preschool wheezing that will spontaneously enter remission is:

9. The greatest predictor for remission of persistent childhood asthma is:

10. Possible benefits of early initiation of biologic therapy for achieving remission in mild-to-moderate asthma include:

11. When used for the induction of asthma remission, azithromycin is effective for:

12. Lower clinical remission rates have been reported in biologic-treated patients with severe asthma and with:

13. The pathophysiology of COPD increases the risk for developing:

14. Meta-analysis of retrospective studies of patients with both COPD and CVD determined that beta-blocker therapy reduced:

15. Cardiovascular events are the most common cause of death in patients with COPD during and following a moderate/severe exacerbation and during exacerbation-free periods.